Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Vir Biotechnology, Inc.
– To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide – – In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration...
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
October 21, 2021 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter...
The Oligonucleotide Therapeutics Society Presents the 2021 Virtual Conference
September 04, 2021 11:00 ET
|
Oligonucleotide Therapeutics Society
SAN DIEGO, Sept. 04, 2021 (GLOBE NEWSWIRE) -- The Oligo Meeting is purposefully designed to bring people together to share incredible advancements in the field of oligonucleotide therapeutics. While...
Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
July 15, 2021 08:30 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 MARCH (Monoclonal Antibody siRNA...
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
July 06, 2021 09:00 ET
|
Auris Medical AG
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
June 25, 2021 08:50 ET
|
Vir Biotechnology, Inc.
– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel HBV therapies administrated as monotherapy or in combination with other agents – – Management to host conference...
Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
April 21, 2021 08:00 ET
|
Vir Biotechnology, Inc.
DURHAM, N.C. and BEIJING and SAN FRANCISCO and CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Brii Biosciences (“Brii Bio”), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc....
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
February 25, 2021 16:01 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended...
NapaJen Pharma Reports Positive Results from Phase 1 Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
October 08, 2020 07:35 ET
|
NapaJen
NJA-730 is an Anti-CD-40 Oligonucleotide Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease (aGvHD) Treatment Shown to be Safe and Well-Tolerated...
MicroCures Advances Burn Wound Healing Program Under Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR)
January 28, 2020 08:05 ET
|
MicroCures, Inc.
$1 Million in Funding from the USAISR Supporting Collaborative Research Project Pilot Animal Study Successfully Completed; Larger Preclinical Study Underway NEW YORK, Jan. 28, 2020 (GLOBE...